Association of the GGCX (CAA)16/17 repeat polymorphism with higher warfarin dose requirements in African Americans

Pharmacogenetics and Genomics

Volumn 22, Issue 2, 2012, Pages 152-158

  Cavallari, Larisa H ^a   Perera, Minoli ^c   Wadelius, Mia ^d   Deloukas, Panos ^e   Taube, Gelson ^a   Patel, Shitalben R ^a   Aquino Michaels, Keston ^c   Viana, Marlos A G ^a,b   Shapiro, Nancy L ^a   Nutescu, Edith A ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d UPPSALA UNIVERSITY   (Sweden)

^e WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

Author keywords

African American; c glutamyl carboxylase; warfarin

Indexed keywords

CARBOXYLASE; GAMMA GLUTAMYL CARBOXYLASE; REPETITIVE DNA; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE COMPLEX 1; WARFARIN;

ADULT; AFRICAN AMERICAN; AGE; AGED; ARTICLE; BODY SIZE; DNA POLYMORPHISM; DOSE RESPONSE; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE;

EID: 84855921127     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32834f288f     Document Type: Article

References (42)

1. Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE, Selby JV, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003; 349:1019-1026. (Pubitemid 37087616)
2. Monreal M, Roncales FJ, Ruiz J, Muchart J, Fraile M, Costa J, et al. Secondary prevention of venous thromboembolism: a role for low-molecular-weight heparin. Haemostasis 1998; 28:236-243. (Pubitemid 29329828)
3. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008; 133:160S-198S. (Pubitemid 351892967)
4. Absher RK, Moore ME, Parker MH. Patient-specific factors predictive of warfarin dosage requirements. Ann Pharmacother 2002; 36: 1512-1517.
5. Scordo MG, Pengo V, Spina E, Dahl ML, Gusella M, Padrini R. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin Pharmacol Ther 2002; 72:702-710. (Pubitemid 36021009)
6. Wang D, Chen H, Momary KM, Cavallari LH, Johnson JA, Sadee W. Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement. Blood 2008; 112:1013-1021.
7. Higashi MK, Veenstra DL, Kondo LM,Wittkowsky AK, Srinouanprachanh SL, Farin FM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002; 287:1690-1698. (Pubitemid 34289221)
8. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005; 352:2285-2293. (Pubitemid 40740552)
9. Cavallari LH, Langaee TY, Momary KM, Shapiro NL, Nutescu EA, Coty WA, et al. Genetic and clinical predictors of warfarin dose requirements in African Americans. Clin Pharmacol Ther 2010; 87:459-464.
10. Limdi NA,Wadelius M, Cavallari L, Eriksson N, Crawford DC, Lee MT, et al. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood 2010; 115:3827-3834.
11. Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009; 360:753-764.
12. Wadelius M, Chen LY, Lindh JD, Eriksson N, Ghori MJ, Bumpstead S, et al. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 2009; 113:784-792.
13. Cooper GM, Johnson JA, Langaee TY, Feng H, Stanaway IB, Schwarz UI, et al. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 2008; 112:1022-1027.
14. Takeuchi F, McGinnis R, Bourgeois S, Barnes C, Eriksson N, Soranzo N, et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet 2009; 5:e1000433.
15. Cha PC, Mushiroda T, Takahashi A, Kubo M, Minami S, Kamatani N, et al. Genome-wide association study identifies genetic determinants of warfarin responsiveness for Japanese. Hum Mol Genet 2011; 19:4735-4744.
16. Coumadin (warfarin sodium) package insert. Princeton, NJ: Bristol-Myers Squibb; 2010.
17. Limdi NA, Beasley TM, Crowley MR, Goldstein JA, Rieder MJ, Flockhart DA, et al. VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans. Pharmacogenomics 2008; 9:1445-1458.
18. Rost S, Fregin A, Koch D, Compes M, Muller CR, Oldenburg J. Compound heterozygous mutations in the gamma-glutamyl carboxylase gene cause combined deficiency of all vitamin K-dependent blood coagulation factors. Br J Haematol 2004; 126:546-549. (Pubitemid 39093097)
19. Kimura R, Miyashita K, Kokubo Y, Akaiwa Y, Otsubo R, Nagatsuka K, et al. Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients. Thromb Res 2007; 120:181-186. (Pubitemid 46754413)
20. Chen LY, Eriksson N, Gwilliam R, Bentley D, Deloukas P, Wadelius M. Gamma-glutamyl carboxylase (GGCX) microsatellite and warfarin dosing. Blood 2005; 106:3673-3674. (Pubitemid 41609210)
21. Wadelius M, Chen LY, Downes K, Ghori J, Hunt S, Eriksson N, et al. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J 2005; 5:262-270. (Pubitemid 41131718)
22. King CR, Deych E, Milligan P, Eby C, Lenzini P, Grice G, et al. Gammaglutamyl carboxylase and its influence on warfarin dose. Thromb Haemost 2010; 104:750-754.
23. Database of Single Nucleotide Polymorphisms (dbSNP). Bethesda (MD): National Center for Biotechnology Information, National Library of Medicine. dbSNP accession: ss147640006, ss52069384 (dbSNP Build ID:132). Available at: http://www.ncbi.nlm.nih.gov/SNP/. [Accessed 24 October 2011].
24. Perera MA, Gamazon E, Cavallari LH, Patel SR, Poindexter S, Kittles RA, et al. The missing association: sequencing-based discovery of novel SNPs in VKORC1 and CYP2C9 that affect warfarin dose in African Americans. Clin Pharmacol Ther 2011; 89:408-415.
25. Rost S, Fregin A, Ivaskevicius V, Conzelmann E, Hortnagel K, Pelz HJ, et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 2004; 427:537-541. (Pubitemid 38209110)
26. Hruska MW, Frye RF, Langaee TY. Pyrosequencing method for genotyping cytochrome P450 CYP2C8 and CYP2C9 enzymes. Clin Chem 2004; 50:2392-2395. (Pubitemid 39552182)
27. Cavallari LH, Butler C, Langaee TY,Wardak N, Patel SR, Viana MAG, et al. Association of apolipoprotein E genotype with duration of time to achieve a stable warfarin dose in African-American patients. Pharmacotherapy 2011; 31:785-792.
28. Wadelius M, Sorlin K, Wallerman O, Karlsson J, Yue QY, Magnusson PK, et al.Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors. Pharmacogenomics J 2004; 4:40-48. (Pubitemid 38256604)
29. Shikata E, Ieiri I, Ishiguro S, Aono H, Inoue K, Koide T, et al. Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and gamma-glutamyl carboxylase) gene variants with warfarin sensitivity. Blood 2004; 103:2630-2635. (Pubitemid 38393017)
30. Rieder MJ, Reiner AP, Rettie AE. Gamma-glutamyl carboxylase (GGCX) tagSNPs have limited utility for predicting warfarin maintenance dose. J Thromb Haemost 2007; 5:2227-2234. (Pubitemid 47617875)
31. Cha PC, Mushiroda T, Takahashi A, Saito S, Shimomura H, Suzuki T, et al. High-resolution SNP and haplotype maps of the human gamma-glutamyl carboxylase gene (GGCX) and association study between polymorphisms in GGCX and the warfarin maintenance dose requirement of the Japanese population. J Hum Genet 2007; 52:856-864. (Pubitemid 47512854)
32. Harrington DJ, Gorska R,Wheeler R, Davidson S, Murden S, Morse C, et al. Pharmacodynamic resistance to warfarin is associated with nucleotide substitutions in VKORC1. J Thromb Haemost 2008; 6: 1663-1670.
33. De Oliveira Almeida VC, De Souza Ferreira AC, Ribeiro DD, Gomes Borges KB, Salles Moura Fernandes AP, Brunialti Godard AL. Association of the C3435T polymorphism of the MDR1 gene and therapeutic doses of warfarin in thrombophilic patients. J Thromb Haemost 2011; 9:2120-2122.
34. Limdi NA, Arnett DK, Goldstein JA, Beasley TM, McGwin G, Adler BK, et al. Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans. Pharmacogenomics 2008; 9:511-526. (Pubitemid 351803913)
35. Herman D, Peternel P, Stegnar M, Breskvar K, Dolzan V. The influence of sequence variations in factor VII, gamma-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement. Thromb Haemost 2006; 95:782-787.
36. Loebstein R, Vecsler M, Kurnik D, Austerweil N, Gak E, Halkin H, et al. Common genetic variants of microsomal epoxide hydrolase affect warfarin dose requirements beyond the effect of cytochrome P450 2C9. Clin Pharmacol Ther 2005; 77:365-372. (Pubitemid 40719265)
37. Vecsler M, Loebstein R, Almog S, Kurnik D, Goldman B, Halkin H, et al. Combined genetic profiles of components and regulators of the vitamin Kdependent gamma-carboxylation system affect individual sensitivity to warfarin. Thromb Haemost 2006; 95:205-211.
38. Huang SW, Xiang DK, Huang L, Chen BL, An BQ, Li GF, et al. Influence of GGCX genotype on warfarin dose requirements in Chinese patients. Thromb Res 2011; 127:131-134.
39. Hirsh J, Fuster V, Ansell J, Halperin JL. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation 2003; 107:1692-1711. (Pubitemid 36397341)
40. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, et al. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 2010; 121:e46-e215.
41. White RH, DagerWE, Zhou H, Murin S. Racial and gender differences in the incidence of recurrent venous thromboembolism. Thromb Haemost 2006; 96:267-273. (Pubitemid 44377808)
42. Schneider D, Lilienfeld DE, ImW. The epidemiology of pulmonary embolism: racial contrasts in incidence and in-hospital case fatality. J Natl Med Assoc 2006; 98:1967-1972. (Pubitemid 44955943)